Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Pulmonary/Respiratory Diseases | Cardiology/Vascular Diseases | Hepatology (Liver, Pancreatic, Gall Bladder) | Genetic Disease
Cystic Fibrosis Clinical Trials
A listing of Cystic Fibrosis medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : UAB/CHS Cystic Fibrosis Center
I Change Adherence & Raise Expectations
Birmingham : Site Reference ID/Investigator# 78920
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Birmingham : University of Alabama at Birmingham
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
Birmingham : The University of Alabama at Birmingham
Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis
Birmingham :
Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CTFR Gating Mutation
View More »
Birmingham :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Birmingham : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Mobile :
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
Alaska
Anchorage : Site Reference ID/Investigator# 79256
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Arizona
Phoenix : Phoenix Children's Hospital
I Change Adherence & Raise Expectations
Tucson : University of Arizona Medical Center
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
Tucson :
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
Arkansas
Little Rock :
A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eFlow Rapid Nebulizer System in Patients With Cystic Fibrosis
Little Rock : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Little Rock : Site Reference ID/Investigator# 79265
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
California
La Jolla : University of California - San Diego
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
Los Angeles : University of Southern California
Prospective Observational Study to Evaluate Biomarkers of Aminoglycoside Nephrotoxicity in Patients With Cystic Fibrosis
Oakland : Kaiser Permanente Medical Care Program
I Change Adherence & Raise Expectations
Oakland : Site Reference ID/Investigator# 79295
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Oakland : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
View More »
Palo Alto : Updated
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
Palo Alto :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Colorado
Aurora : Site Reference ID/Investigator# 79277
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Aurora : Children's Hospital Colorado
Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation
Denver : Site Reference ID/Investigator# 76784
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Denver : National Jewish Health
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
Denver :
Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function
View More »
Denver : National Jewish Hospital
Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis
Connecticut
Hartford : Connecticut Children's Medical Center
I Change Adherence & Raise Expectations
Hartford :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
New Haven : Site Reference ID/Investigator# 78940
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Delaware
Wilmington : Site Reference ID/Investigator# 78945
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Wilmington : Alfred I. duPont Hospital for Children
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
District of Columbia
Washington : Site Reference ID/Investigator# 79373
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Washington DC : Children's National Medical Center
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
Florida
Altamonte Springs : Site Reference ID/Investigator# 76776
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Altamonte Springs : Central Florida Pulmonary Group
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
Gainesville : Site Reference ID/Investigator# 76790
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Gainesville : Site Reference ID/Investigator# 78928
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Jacksonville : Site Reference ID/Investigator# 78898
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
View More »
Miami : University of Miami
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
Orlando : Site Reference ID/Investigator# 78917
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Orlando : Site Reference ID/Investigator# 96075
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Orlando : Nemours Children's Clinic - Orlando
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
St. Petersburg : Site Reference ID/Investigator# 79264
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Tampa : Site Reference ID/Investigator# 76783
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Tampa :
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
Georgia
Atlanta : Site Reference ID/Investigator# 79394
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Atlanta : Children's Healthcare of Atlanta at Scottish Rite
Prevention of Cystic Fibrosis Diabetes
Atlanta : Emory University
Prevention of Cystic Fibrosis Diabetes
Augusta : Site Reference ID/Investigator# 79395
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Idaho
Boise : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Illinois
Chicago : Children's Memorial Hospital
I Change Adherence & Raise Expectations
Chicago : Site Reference ID/Investigator# 79296
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Chicago :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Chicago : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Indiana
Evansville :
A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects
Indianapolis : Riley Hospital for Children
I Change Adherence & Raise Expectations
Indianapolis : Site Reference ID/Investigator# 78903
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Indianapolis : Riley Hospital for Children
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
Indianapolis :
Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CTFR Gating Mutation
View More »
Indianapolis :
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
Iowa
Iowa City :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Kansas
Kansas City : University of Kansas Medical Center
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
Kentucky
Lexington :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Louisiana
New Orleans : Site Reference ID/Investigator# 78916
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Maine
Portland : Maine Medical Center
I Change Adherence & Raise Expectations
Portland : Site Reference ID/Investigator# 78894
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Maryland
Baltimore : Johns Hopkins University
Durability of Hypertonic Saline for Enhancing Mucociliary Clearance in Cystic Fibrosis
Baltimore : Site Reference ID/Investigator# 78893
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Baltimore :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Massachusetts
Boston : Children's Hospital Boston
I Change Adherence & Raise Expectations
Boston : Site Reference ID/Investigator# 78895
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Boston : Site Reference ID/Investigator# 79254
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Boston : Site Reference ID/Investigator# 79276
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Boston : Boston Children's Hospital
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
View More »
Boston : Updated
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
Boston : Children's Hospital Boston
Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis
Boston : Children's Hosptital, Boston
Structure and Function of Salivary Proteins
Boston :
Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CTFR Gating Mutation
Boston :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Boston : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Boston :
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
Worcester : Site Reference ID/Investigator# 78954
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Michigan
Ann Arbor : University of Michigan Health System
I Change Adherence & Raise Expectations
Detriot :
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
Detroit : Harper University Hospital
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
Detroit :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
East Lansing : Site Reference ID/Investigator# 78950
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
View More »
Farmington Hills : Site Reference ID/Investigator# 79278
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Grand Rapids : Site Reference ID/Investigator# 79397
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Grand Rapids :
Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CTFR Gating Mutation
Grand Rapids :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Grand Rapids : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Grand Rapids :
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
Minnesota
Minneapolis : University of Minnesota
A Study of Sweat Testing Using a Quantitative Patch
Minneapolis : Site Reference ID/Investigator# 76791
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Minneapolis : Site Reference ID/Investigator# 79253
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Minneapolis : University of Minnesota - Cystic Fibrosis Center
Prospective Observational Study to Evaluate Biomarkers of Aminoglycoside Nephrotoxicity in Patients With Cystic Fibrosis
Missouri
Kansas City : Site Reference ID/Investigator# 78948
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Kansas City :
Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CTFR Gating Mutation
Kansas City : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Kansas City :
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
St. Louis : Site Reference ID/Investigator# 79275
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
View More »
St. Louis :
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
Nebraska
Omaha : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Omaha :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Nevada
Las Vegas : Children's Lung Specialists
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
New Hampshire
Bedford : Dartmouth Hitchcock Specialty Care Clinic
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
Lebanon : Dartmouth Hitchcock Medical Center
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
Manchester : Site Reference ID/Investigator# 78957
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
New Jersey
Long Branch : Site Reference ID/Investigator# 78901
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Long Branch : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Morristown : Site Reference ID/Investigator# 76782
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
New Mexico
Albuquerque : UNM Clinical and Translational Center
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
New York
Great Neck : Biomedical Research Alliance of New York
Cystic Fibrosis - Pediatric
New Hyde Park : Biomedical Research Alliance of New York
Cystic Fibrosis
View More »
Albany :
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
Buffalo : Women and Children's Hospital of Buffalo
I Change Adherence & Raise Expectations
Buffalo : Site Reference ID/Investigator# 78941
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
New Hyde Park : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
New Hyde Park :
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
New York : Site Reference ID/Investigator# 76773
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
New York :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Rochester : University of Rochester Medical Center
I Change Adherence & Raise Expectations
Rochester : Site Reference ID/Investigator# 92713
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Syracuse : Site Reference ID/Investigator# 78912
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Syracuse : SUNY Upstate University
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
Syracuse :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Valhalla :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
North Carolina
Chapel Hill : UNC-Chapel Hill
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
Chapel Hill : Site Reference ID/Investigator# 78937
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Chapel Hill : UNC Hospitals
Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability
Chapel Hill : UNC at Chapel Hill
Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis
Chapel Hill :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
View More »
Chapel Hill : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Durham : Duke University Medical Center
I Change Adherence & Raise Expectations
Durham : Duke University Medical Center
Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability
North Dakota
Bismarck : St. Alexius Medical Center
A study for cystic fibrosis patients who might have a condition called Fibrosing Colonopathy (FC).
View More »
Bismark : Site Reference ID/Investigator# 78958
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Ohio
Akron : Akron Children's Hospital
I Change Adherence & Raise Expectations
Akron : Site Reference ID/Investigator# 79263
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Cincinnati : Site Reference ID/Investigator# 79375
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Cincinnati : Cincinnati Children's Hospital
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
Cincinnati : UC Health - University of Cincinnati
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
View More »
Cincinnati : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Cincinnati :
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
Cleveland : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Cleveland : Rainbow Babies and Children's Hospital
I Change Adherence & Raise Expectations
Cleveland :
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
Columbus : Nationwide Children's Hospital
I Change Adherence & Raise Expectations
Columbus : Site Reference ID/Investigator# 78897
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Columbus : Nationwide Children's Hospital, Ohio State University
Prevention of Cystic Fibrosis Diabetes
Columbus : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Columbus : Nationwide Children's Hospital
Use of Levemir® Improves Metabolic and Clinical Status in Cystic Fibrosis-related Diabetes (CFRD)
Dayton : Site Reference ID/Investigator# 78915
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Dayton :
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
Toledo : Toledo Children's Hospital
I Change Adherence & Raise Expectations
Toledo : Site Reference ID/Investigator# 78913
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Toledo :
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
Oklahoma
Oklahoma City : Santiago Reyes, MD
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
Oklahoma City : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Oklahoma City :
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
Pennsylvania
Hershey : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Hershey :
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
Philadelphia : Site Reference ID/Investigator# 76777
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Philadelphia :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Pittsburgh :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
View More »
Pittsburgh : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Pittsburgh :
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
South Carolina
Charleston : Medical University of South Carolina
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
Charleston : Medical University of South Carolina
Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis
Charleston :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Charleston : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Charleston :
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
View More »
Washington :
A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eFlow Rapid Nebulizer System in Patients With Cystic Fibrosis
South Dakota
Sioux Falls :
A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eFlow Rapid Nebulizer System in Patients With Cystic Fibrosis
Sioux Falls : Site Reference ID/Investigator# 78909
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Tennessee
Memphis : Children's Foundation Research Institute/UTHSC
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
Nashville :
A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eFlow Rapid Nebulizer System in Patients With Cystic Fibrosis
Nashville :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Texas
Austin : Site Reference ID/Investigator# 79213
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Dallas :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Dallas :
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
Fort Worth : Site Reference ID/Investigator# 78949
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Fort Worth :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
View More »
Houston :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
San Antonio :
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
Tyler : Site Reference ID/Investigator# 79261
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Utah
Salt Kale City : Primary Children's Medical Center
I Change Adherence & Raise Expectations
Salt Lake City : University of Utah
A Study of Sweat Testing Using a Quantitative Patch
Salt Lake City :
Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CTFR Gating Mutation
Salt Lake City :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Salt Lake City : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Vermont
Colchester : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Virginia
Charlottesville : Site Reference ID/Investigator# 78942
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Charlottesville : University of Virginia
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
Norfolk : Site Reference ID/Investigator# 79293
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Richmond : Site Reference ID/Investigator# 78955
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Richmond :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Washington
Seattle : Seattle Children's Hospital
I Change Adherence & Raise Expectations
Seattle :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Seattle : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Spokane : Site Reference ID/Investigator# 79257
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
West Virginia
Morgantown : West Virginia University
I Change Adherence & Raise Expectations
Morgantown : Site Reference ID/Investigator# 78953
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Morgantown :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Wisconsin
Madison : American Family Children's Hospital
A Study of Sweat Testing Using a Quantitative Patch
Madison : Site Reference ID/Investigator# 78944
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Madison :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Milwaukee : Site Reference ID/Investigator# 79294
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Any Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Milwaukee : Childrens Hospital of Wisconsin
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
View More »
Milwaukee :
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
Argentina
Buenos Aires : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Paraná Entre Ríos : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Australia
Clayton : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
New Lambton Heights : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Parkville : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Belgium
Antwerp : University Hospital Antwerp - Universitair Ziekenhuis Antwerpen (UZA)
Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.
Bulgaria
Pleven : Clinic of Paediatric Diseases at UMHAT Dr Georgi Stranski
Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.
Plovdiv : Clinic of Genetic and Paediatric Diseases at UMHAT Sveti Georgi
Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.
Ruse : Specialized Hospital for Active Treatment of Pulmological and Phtisiatric Disease
Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.
Varna : Multiprofile Clinic for Specialized Pediatric Clinic at MHAT Sveta Marina
Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.
Canada
Calgary : Novartis Investigative Site
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
Halifax : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Montreal : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Montreal : Novartis Investigative Site
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
Toronto : Novartis Investigative Site
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
View More »
Toronto : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Vancouver : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Winnipeg : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
France
Bron : Centre de ressources et de compétences pour la mucovisidose, enfants
Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus®
Lyon : Centre de Ressource et de Compétence Mucoviscidose Pédiatrique Centre de Référence Mucoviscidose
Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® /Pulmoaid® in Patients With Cystic Fibrosis
Germany
Berlin : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Bochum : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Bochum : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Dresden : Novartis Investigative Site
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
Erlangen : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
View More »
Essen : Novartis Investigative Site
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
Frankfurt : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Frankfurt : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Frankfurt : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Hannover : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Jena : Jena University Hospital, Universitaetsklinikum Jena
Control of Steatorrhea in Patients With Cystic Fibrosis and Pancreatic Insufficiency
Jena : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Koeln : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Koln : Novartis Investigative Site
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
München : Klinikum der Universitat Munchen Medizinische Klinik-Innenstadt
Control of Steatorrhea in Patients With Cystic Fibrosis and Pancreatic Insufficiency
Munich : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Tubingen : University Children's Clinic Tubingen
Control of Steatorrhea in Patients With Cystic Fibrosis and Pancreatic Insufficiency
Greece
Patras : Novartis Investigative site
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
Thessaloniki : Novartis Investigative Site
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
Hungary
Budapest : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Debrecen : Novartis Investigative Site
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
Kaposvar : Novartis Investigative Site
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
Szeged : Novartis Investigative Site
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
Italy
Firenze : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Messina : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Napoli : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Roma : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Japan
Kagawa : Site Reference ID/Investigator# 65530
Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Kagoshima : Site Reference ID/Investigator# 65527
Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Kanazawa : Site Reference ID/Investigator# 65529
Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Nagoya : Site Reference ID/Investigator# 73813
Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Nagoya : Site reference ID/Investigator # 96698
Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
View More »
Obu : Site reference ID/Investigator # 93736
Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Sendai : Site Reference ID/Investigator# 65528
Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Tokyo : Site Reference ID/Investigator# 67122
Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Tsukuba : Site Reference ID/Investigator# 88673
Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Tsukuba : Site reference ID/Investigator # 93735
Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Mexico
Monterrey : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Poland
Gdansk : Specjalistyczny Zespół Opieki Zdrowotnej nad Matką i Dzieckiem Poradnia Leczenia Mukowiscydozy
Control of Steatorrhea in Patients With Cystic Fibrosis and Pancreatic Insufficiency
Gdansk : Specjalistyczny Zespot Opieki Zdrowotnej nad Matka i Dzieckiem Poradnia Leczenia Mukowiscydozy
Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.
Karpacz : Centrum Pulmonologii i Alergologii w Karpaczu
Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.
Lodzi : Wojewodzki Szpital Specjalistyczny im Kopernika
Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.
Lublin : Dziecięcy Szpital Kliniczny im. Prof. Antoniego Gębali
Control of Steatorrhea in Patients With Cystic Fibrosis and Pancreatic Insufficiency
View More »
Lublin : ALERGOTEST s.c Specjalistyczne Centrum Medyczne
Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.
Poznan : Szpital Kliniczny im Karola Jonschera
Control of Steatorrhea in Patients With Cystic Fibrosis and Pancreatic Insufficiency
Poznan : Szpital Kliniczny im Karola Jonschera
Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.
Rabka Zdrój : NZOZ Sanatorium Cassia Villa Medica
Control of Steatorrhea in Patients With Cystic Fibrosis and Pancreatic Insufficiency
Rabka Zdrój : NZOZ Sanatorium Cassia Villa Medica
Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.
Rzeszow : NZOZ Podkarpacki Osrodek Pulmonologii i Alergologii
Control of Steatorrhea in Patients With Cystic Fibrosis and Pancreatic Insufficiency
Rzeszow : NZOZ Podkarpacki Osrodek Pulmonologii i Alergologii
Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.
Warszawa : IRMED Irena Wojciechowska
Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.
Warszawa : Centrum Zdrowia Matki, Dziecka i Mlodziezy
Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.
Qatar
Doha : Hamad Medical Corporation
Blood Collection From Individuals With Lung Disease for Genetic Studies (Qatar)
Russian Federation
Kazan : Novartis Investigative Site
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
Moscow : Novartis Investigative Site
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
Voronezh : Novartis Investigative Site
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
Yaroslavl : Novartis Investigative Site
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
Spain
Barcelona : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Sabadell : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Valencia : Novartis Investigative Site
Assess the Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Switzerland
Lausanne : Novartis Investigative Site
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
Zurich : Novartis Investigative Site
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
United Kingdom
Belfast : Celerion
A Safety and Tolerability Study OF PUR118 In Subjects With Cystic Fibrosis
Belfast :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
Cambridge : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Cardiff : Vertex Investigational Site
Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation
Edinburgh :
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
View More »
Liverpool : Liverpool Heart & Chest Hospital
A Cross-over Study of OligoG in Subjects With Cystic Fibrosis. Fibrosis
Liverpool : Liverpool Heart and Chest Hospital
Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.
London : Royal Brompton Hospital, Department of Respiratory Medicine
Extension Study of Arikace™ in CF Patients With Chronic Pseudomonas Aeruginosa Infection
Sheffield : Sheffield Children's Hospital, The Academic Unit of Child Health
Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.